CSPC Pharmaceutical Group Limited (CSPCY)

Market Cap	12.27B +13.1%
Revenue (ttm)	4.61B +20.5%
Net Income	1.09B +92.7%
EPS	0.38 +94.6%
Shares Out	n/a
PE Ratio	11.15
Forward PE	10.82
Dividend	0.17 (3.94%)
Ex-Dividend Date	Oct 21, 2026

Volume	57
Open	4.320
Previous Close	4.273
Day's Range	4.270 - 4.320
52-Week Range	3.260 - 5.460
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 18, 2026

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 18,626
• Stock Exchange: OTCMKTS
• Ticker Symbol: CSPCY

Financial Performance

In 2025, CSPC Pharmaceutical Group's revenue was 26.01 billion, a decrease of -10.35% compared to the previous year's 29.01 billion. Earnings were 3.88 billion, a decrease of -10.30%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error